Abbott Laboratories Stock NEO Exchange
Stocks
ABT
CA0028221046
Medical Equipment, Supplies & Distribution
| Market Cap | 187B 161B 152B 139B 259B 17,698B 260B 1,793B 696B 9,081B 704B 689B 29,253B | P/E 2026 * |
31.1x | P/E 2027 * | 23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 211B 182B 171B 156B 292B 19,959B 293B 2,022B 785B 10,240B 794B 776B 32,989B | EV / Sales 2026 * |
4.2x | EV / Sales 2027 * | 3.81x |
| Free-Float |
86.16% | Yield 2026 * |
2.37% | Yield 2027 * | 2.53% |
Last Transcript : Abbott Laboratories
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 52 | 31/03/2020 |
Philip Boudreau
DFI | Director of Finance/CFO | 53 | 01/09/2023 |
Sabina Ewing
CIO | Chief Investment Officer | 51 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Sally Blount
BRD | Director/Board Member | 64 | 09/12/2011 |
Nancy McKinstry
BRD | Director/Board Member | 67 | 09/12/2011 |
Daniel Starks
BRD | Director/Board Member | 71 | 16/02/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 187B | |
| -0.42% | -3.68% | -18.51% | +7.39% | 187B | |
| +1.15% | +3.22% | +1.37% | +17.42% | 120B | |
| -1.86% | +2.77% | +13.15% | +91.44% | 63.15B | |
| -1.31% | -1.09% | +17.67% | +43.65% | 51.75B | |
| -1.54% | -2.52% | -3.98% | -32.30% | 50.32B | |
| -2.02% | -3.22% | +9.18% | -12.39% | 33.17B | |
| 0.00% | +3.71% | - | - | 32.1B | |
| -0.81% | +0.74% | +35.59% | -15.78% | 23.93B | |
| -1.44% | -4.21% | -8.07% | +11.30% | 22.99B | |
| Average | -0.82% | -0.07% | +5.80% | +13.84% | 65.03B | |
| Weighted average by Cap. | -0.42% | +0.02% | -1.43% | +16.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 50.3B 43.29B 40.73B 37.2B 69.59B 4,749B 69.78B 481B 187B 2,437B 189B 185B 7,850B | 54.65B 47.02B 44.24B 40.41B 75.6B 5,159B 75.81B 523B 203B 2,647B 205B 201B 8,528B |
| Net income | 6.23B 5.36B 5.05B 4.61B 8.62B 588B 8.65B 59.62B 23.14B 302B 23.4B 22.89B 973B | 7.92B 6.82B 6.42B 5.86B 10.96B 748B 10.99B 75.81B 29.42B 384B 29.76B 29.11B 1,237B |
| Net Debt | 23.94B 20.6B 19.38B 17.7B 33.12B 2,260B 33.21B 229B 88.87B 1,160B 89.89B 87.93B 3,736B | 20.96B 18.03B 16.97B 15.5B 28.99B 1,979B 29.07B 200B 77.8B 1,015B 78.7B 76.98B 3,271B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
